It is well known that the next phase of the Brilac
Post# of 72447
(Total Views: 261)
Posted On: 03/22/2018 1:42:39 PM
It is well known that the next phase of the Brilacidin-ABSSSI clinical trial will cost 30 million dollars. Because the shorts and bashers knocked the price of the stock down from nearly 5 to a couple of bucks, and then worse, it would have been foolish for the company to dilute the stock to get that 30 million dollars.
Instead, the company wisely chose to do the much less expensive clinical trials for Brilacidin-OM (oral mucositis), Brilacidin-UP (ulcerative proctitis), and Prurisol (psoriasis), rather than doing the multi-year, incredibly expensive ABSSSI trial. The company also has done a smaller Kevetrin clinical trial.
It is ABSOLUTELY the fault of the bashers/shorters that the stock price has been attacked in a concerted effort to make the stock price fall, so that the responsible decision of management was to defer the expensive trials in favor of the fast, much cheaper ones.
I ABSOLUTELY blame bashers like the nasty manifestation of a multi-identity who has appeared here, bashing the company and blaming the management. I am sure that he/she/it is sorely disappointed that the smart CEO of IPIX did not fall into the trap that OCAT stumbled into. OCAT was mercilessly attacked by the same scum (Mako and cohorts) that attacked IPIX. The difference is that OCAT foolishly took on toxic financing, and when their drug had spectacular results, they sold the company for far less than its value.
IPIX has not made that mistake. I remain confident in IPIX management.
I also remain confident that the shorts and bashers are revealing themselves, both as outright bashers and as soft bashers, and that their day of doom will come.
Instead, the company wisely chose to do the much less expensive clinical trials for Brilacidin-OM (oral mucositis), Brilacidin-UP (ulcerative proctitis), and Prurisol (psoriasis), rather than doing the multi-year, incredibly expensive ABSSSI trial. The company also has done a smaller Kevetrin clinical trial.
It is ABSOLUTELY the fault of the bashers/shorters that the stock price has been attacked in a concerted effort to make the stock price fall, so that the responsible decision of management was to defer the expensive trials in favor of the fast, much cheaper ones.
I ABSOLUTELY blame bashers like the nasty manifestation of a multi-identity who has appeared here, bashing the company and blaming the management. I am sure that he/she/it is sorely disappointed that the smart CEO of IPIX did not fall into the trap that OCAT stumbled into. OCAT was mercilessly attacked by the same scum (Mako and cohorts) that attacked IPIX. The difference is that OCAT foolishly took on toxic financing, and when their drug had spectacular results, they sold the company for far less than its value.
IPIX has not made that mistake. I remain confident in IPIX management.
I also remain confident that the shorts and bashers are revealing themselves, both as outright bashers and as soft bashers, and that their day of doom will come.
(9)
(0)